SCHEMBL25324925

SCHEMBL25324925

CC(C)(C)OC(=O)N1CCc2c(nc(Cl)nc2OCc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 5/20 0.47
PARP1 P09874 1/20 0.45
TNKS2 Q9H2K2 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
C5AR1 P21730 1/20 0.44
ESR2 Q92731 1/20 0.43
GCK P35557 1/20 0.42
ACHE P22303 1/20 0.41
PDE10A Q9Y233 1/20 0.41
MAPT P10636 1/20 0.41
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
TLR9 Q9NR96 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
PRMT5 O14744 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
MAPK1 P28482 1/20 0.40
MTOR P42345 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30915380 0.91 C5AR1 (0.42) P2RX3C5AR1ACHEOPRD1OPRK1
SCHEMBL30915382 0.91 C5AR1 (0.42) P2RX3C5AR1ACHEOPRD1OPRK1
SCHEMBL20955091 0.90 P2RX3 (0.49) P2RX3PARP1TNKS2PARP2ESR2
SCHEMBL23415264 0.87 P2RX3 (0.46) P2RX3PARP1TNKS2PARP2ESR2
SCHEMBL29888418 0.86 GCK (0.47) P2RX3PARP1TNKS2PARP2GCK
SCHEMBL24730877 0.86 GCK (0.47) P2RX3PARP1TNKS2PARP2GCK
SCHEMBL27191171 0.85 P2RX3 (0.53) P2RX3PARP1TNKS2PARP2ESR2
SCHEMBL31138506 0.82 USP1 (0.38) P2RX3PARP1TNKS2PARP2GPR119
SCHEMBL19616716 0.82 TMEM97 (0.47) P2RX3PARP1TNKS2PARP2ACHE
SCHEMBL15440464 0.82 ACHE (0.49) P2RX3PARP1TNKS2PARP2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
EP-4240489-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-09-13 EP disclosed
EP-4216951-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022098625-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-05-12 WO disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS P2RX3 4426/4885PARP1 1158/4885TNKS2 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.